Open AccessCurrent status and future perspectives on neoadjuvant therapy in gastric cancer
Author(s) -
Sheng Ao,
Yuchen Wang,
Qingzhi Song,
Yingjiang Ye,
Guoqing Lyu
Publication year - 2021
Publication title -
chinese journal of cancer research/chinese journal of cancer research
Language(s) - English
Resource type - Journals
eISSN - 1993-0631
pISSN - 1000-9604
DOI - 10.21147/j.issn.1000-9604.2021.02.06
Subject(s) - medicine , neoadjuvant therapy , nat , cancer , pathological , gastrectomy , clinical trial , oncology , population , protocol (science) , intensive care medicine , radiology , surgery , pathology , breast cancer , computer science , alternative medicine , computer network , environmental health
Gastric cancer, with high morbidity and mortality rates, is one of the most heterogeneous tumors. Radical gastrectomy and postoperative chemotherapy are the standard treatments. However, the safety and efficacy of neoadjuvant therapy (NAT) need to be confirmed by many trials before implementation, creating a bottleneck in development. Although clinical benefits of NAT have been observed, a series of problems remain to be solved. Before therapy, more contributing factors should be offered for choice in the intended population and ideal regimens. Enhanced computed tomography (CT) scanning is usually applied to evaluate effectiveness according to Response Evaluation Criteria in Solid Tumors (RECIST), yet CT scanning results sometimes differ from pathological responses. After NAT, the appropriate time for surgery is still empirically defined. Our review aims to discuss the abovementioned issues regarding NAT for GC, including indications, selection of regimens, lesion assessment and NAT-surgery interval time.